



LKT Laboratories, Inc.

TL-32711

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID T4400

CAS No. 1260251-31-7

Chemical Name

Synonym Birinapant

Formula $C_{42}H_{56}F_2N_8O_6$

Formula Wt. 806.94

Melting Point


Purity $\geq 98\%$

Solubility DMSO 100 mg/mL (123.92 mM)
Ethanol 55 mg/mL (68.15 mM)
Water Insoluble

Store Temp -20°C

Ship Temp Ambient

Description TL-32711 is a Smac mimetic that is currently in clinical trials as a potential treatment for a variety of cancers. TL-32711 inhibits members of the inhibitor of apoptosis protein (IAP) family proteins, inducing degradation of cIAP1 and cIAP2. TL-32711 exhibits anticancer chemotherapeutic activity, inhibiting NF- κ B activation and tumor growth in animal models. In acute myelogenous leukemia (AML) cells, this compound induces caspase 8-mediated apoptosis. This compound also improves the efficacy of co-administered antivirals in models of hepatitis B infection.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
T4400	1 mg	\$127.20
T4400	5 mg	\$367.90
T4400	10 mg	\$648.80

References Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. *Proc Natl Acad Sci U S A*. 2015 May 5;112(18):5803-8. PMID: 25902530.

Benetatos CA, Mitsuuchi Y, Burns JM, et al. Birinapant (TL32711), a Bivalent Smac Mimetic, Targets TRAF2-associated cIAPs, Abrogates TNF-induced NF- κ B Activation and is Active in Patient-Derived Xenograft Models. *Mol Cancer Ther*. 2014 Feb 21. [Epub ahead of print]. PMID: 24563541.

Carter BZ, Mak PY, Mak DH, et al. Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. *J Natl Cancer Inst*. 2014 Feb 1;106(2):djt440. PMID: 24526787.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.